Indonesia Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$1995
Buy Report View Sample

Published: September 05, 2022 Report Code: GDHC0058CHR-ST

Select Item

Indonesia Healthcare Market Report Overview

The Indonesia pharmaceutical market size was $8.6 billion in 2021 and the medical devices market size was $3.6 billion in 2021. Indonesia is one of the fastest-growing countries in the Association of Southeast Asian Nations (ASEAN) region, making it one of the most alluring emerging markets for pharmaceutical companies seeking to expand in the Asia-Pacific region.

The Indonesia healthcare market research report is an essential source of information on the analysis of the healthcare, regulatory, and reimbursement landscape in Indonesia. It identifies the key trends in the country’s healthcare market and provides insights into its demographic, regulatory, and reimbursement landscape, and healthcare infrastructure. Most importantly, the report provides valuable insights into the trends and segmentation of its pharmaceutical and medical device markets.

Indonesia Pharmaceuticals Market Report Overview

Market Size (2021) $8.6 billion
Key Segments Generics, Biologics, Biosimilars, and Over-the-Counter (OTC) Medicines
Key Import Partners China, the US, Belgium, Spain, and India
Key Export Partners The Philippines, Singapore, Taiwan, India, and Nigeria
Major Players Sanofi, Novartis, GlaxoSmithKline (GSK), Merck, and Kalbe
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

 Indonesia Medical Devices Market Report Overview

Market Size (2021) $3.6 billion
Major Players Abbott, Fresenius SE & Co. KGaA (Fresenius), GE Healthcare, Terumo, and Smith & Nephew
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Indonesia Healthcare Market – Competitive Landscape

Pharmaceutical Companies: The major players in the Indonesia pharmaceuticals market are Sanofi, Novartis, GlaxoSmithKline (GSK), Merck, and Kalbe.

Medical Devices Companies: The major players in the medical devices market of Indonesia are Abbott, Fresenius SE & Co. KGaA (Fresenius), GE Healthcare, Terumo, and Smith & Nephew.

Indonesia Medical Devices Market Analysis by Players

Indonesia Medical Devices Market Analysis by Players

Buy the Full Report to Know More About Major Players, Download A Free Report Sample

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Indonesia, and includes:

  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers.

  • Profiles and SWOT analyses of the major players in the pharmaceutical market: Sanofi, Novartis, GlaxoSmithKline (GSK), Merck, and Kalbe.

  • Profiles and SWOT analyses of the major players in the medical device market: Abbott, Fresenius, GE Healthcare, Terumo, and Smith and Nephew.

  • An insightful review of the COVID-19 epidemiology, COVID-19 impact and developments in the healthcare market, HealthTech landscape, reimbursement, and regulatory landscape, with analysis covering details of the country’s healthcare reimbursement process, regulatory agencies, and the approval processes for new drugs and medical devices.

  • Detailed analysis of the country’s healthcare policy highlights, demographics, healthcare infrastructure, and healthcare expenditure.

  • An overview of the opportunities for and challenges to growth in the Indonesian healthcare market.

Reasons to Buy

This report will enhance your decision-making capability by allowing you to:

  • Develop business strategies by understanding the trends shaping and driving the Indonesian healthcare market

  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the Indonesian healthcare market in the future

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing competitors’ performance

  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership

Table of Contents

1. Table of Contents

1.1 List of Figures

1.2 List of Tables

2. Executive Summary

2.1 Executive Summary

2.2 Key Highlights: Facts About the Indonesian Healthcare Market

2.3 Key Highlights: Healthcare Startups in Indonesia

2.4 Key Events: Indonesian Healthcare Timeline, 2016–22

2.5 Key Events: Indonesian Pharmaceutical Market

2.6 Key Events: M&As, VC & PE Deals, Global Pharmaceutical Market, 2021–22

2.7 Key Events: Mergers and Acquisitions

2.8 Country Profile, Indonesia, 2021

3. Overview of Pharmaceutical Market

3.1 Pharmaceutical Market – Overview

3.2 Pharmaceutical Market – Exports

3.3 Pharmaceutical Market – Imports

3.4 Pharmaceutical Market – Supply Channels, Indonesia

3.5 Pharmaceutical Market – Market Segments

3.6 Pharmaceutical Market – Market Segments, Generics, Indonesia

3.7 Pharmaceutical Market – Market Segments, Biologics and Biosimilars, Indonesia

3.8 Pharmaceutical Market – Market Segment, Halal Drugs, Indonesia

3.9 Pharmaceutical Market – Market Segment, Traditional Medicines, Indonesia

3.10 Pharmaceutical Market – Market Segment, Over-the-Counter Medicines, Indonesia

3.11 COVID-19 Epidemiology, Indonesia

3.12 COVID-19 Impact and Developments in the Healthcare Market, Indonesia

3.13 COVID-19 Clinical Trials Landscape, Indonesia

3.14 Pharmaceutical Market – Major Players

4. Overview of Medical Devices Market

4.1 Medical Device Market – Overview

4.2 Medical Devices Market – Major Players

5. Pharmaceutical and Medical Devices Market – Drivers and Barriers

5.1 Drivers

5.2 Barriers

6. Deal Analysis

6.1 Deal Analysis: Pharmaceutical Market, Indonesia, 2020–22

6.2 Deal Analysis: Medical Device Market, Indonesia, 2020–22

7. Healthtech Landscape

7.1 Healthtech Landscape, Indonesia

7.2 Healthtech Deals Landscape, Indonesia

7.3 Key Healthtech Deals, Indonesia

7.4 Adoption of Technology in Healthcare, Indonesia

7.5 Digital Healthcare Regulations, Indonesia

7.6 Healthtech Landscape: Benefits and Risks, Indonesia

8. Market Access

8.1 Overview of Healthcare System, Indonesia

8.2 Reimbursement Landscape, Indonesia

8.3 Overview of Insurance Providers, Public Insurance, Indonesia

8.4 Overview of Insurance Providers, Private Insurance, Indonesia

8.5 Healthcare Spending and Prescription Drug Price Trend, Indonesia

8.6 Pricing Policies, Indonesia

8.7 Market Access Timeline, Indonesia, 2013–21

8.8 Regulatory Landscape, Indonesia

8.8.1 Marketing Authorization for Pharmaceutical Products, Indonesia

8.8.2 Marketing Authorization for Medical Devices, Indonesia

8.8.3 Intellectual Property Rights, Patents, Indonesia

8.8.4 Intellectual Property Rights, Trademark, Indonesia

8.8.5 Clinical Trial Regulation Process, Indonesia

8.8.6 Pharmaceutical Clinical Trials Landscape, Indonesia

8.8.7 Pharmaceutical Import and Export, Indonesia

8.8.8 Pharmaceutical Advertising Regulations, Indonesia

8.8.9 Labeling and Packaging Regulations, Indonesia

9. Country Healthcare Landscape

9.1 Indonesian Healthcare Policy Highlights

9.2 Healthcare Facilities and Healthcare Resources, Indonesia

9.3 Life Expectancy and Immunization Rate, Indonesia

9.4 Environmental Health, Indonesia

9.5 Healthcare Personnel, Indonesia

9.6 Disease Burden, Indonesia

9.7 Healthcare Expenditure, Indonesia

10 Trade Associations, Indonesia

11 Trade Fairs, Indonesia

12 Opportunities and Challenges

13 Appendix

13.1 Research Methodology

13.1.1 Coverage

13.1.2 Secondary Research

13.1.3 Forecasts

13.2 Bibliography

13.3 About GlobalData

13.4 Contact Us

13.5 Disclaimer

Table

Table 1: Phase-wise development plan as per the RIPIN, Indonesia, 2022

Table 2: Development plan of biotechnological products and vaccines, Indonesia, 2022

Table 3: COVID-19 indicators (number of cases), Global and Indonesia, 2022

Table 4: COVID-19-related travel restrictions, Indonesia, 2020–22

Table 5: Marketed COVID-19 IVD products, Indonesia, 2021–22

Table 6: Pipeline COVID-19 IVD products, Indonesia, 2021–22

Table 7: Phase-wise development of medical device industry as per the RIPIN, Indonesia, 2022

Table 8: HET for COVID-19 therapeutic drugs, Indonesia, 2021

Table 9: Difference between the OSS and OSS RBA, Indonesia, 2022

Table 10: Drug registration fees, Indonesia, 2022

Table 11: Medical device authorization fees, Indonesia, 2022

Table 12: Patent approval fees, Indonesia, 2022

Table 13: Trademark approval fees, Indonesia, 2022

Table 14: Summary of product characteristics, Indonesia, 2022

Table 15: Pharmaceutical label, Indonesia, 2022

Table 16: Trade fairs, Indonesia, 2022–23

Figures

Figure 1: Pharmaceutical market, revenue ($B), Indonesia, 2012–21

Figure 2: Medical devices market, revenue ($B), Indonesia, 2019–26

Figure 3: Healthcare start-ups in Indonesia, 2022

Figure 4: Country profile, Indonesia, 2021

Figure 5: Pharmaceutical market, revenue ($B), Indonesia, 2012–21

Figure 6: Pharmaceutical market, revenue forecast ($B), Indonesia, 2022–27

Figure 7: Stages of RIPIN, Indonesia, 2022

Figure 8: Pharmaceutical exports ($M), Indonesia, 2014–21

Figure 9: Top export partners, Indonesia, 2021

Figure 10: Pharmaceutical imports ($M), Indonesia, 2014–21

Figure 11: Top import partners, Indonesia, 2021

Figure 12: Pharmaceutical supply channel, Indonesia, 2022

Figure 13: Arrangements of CDOB, Indonesia, 2022

Figure 14: Illustration of service flow and drug supply chain data from producers to primary healthcare facilities, Indonesia, 2022

Figure 15: Proposed solutions on the problems, Indonesia, 2022

Figure 16: Pharmaceutical companies listed on Indonesia Stock Exchange, 2021

Figure 17: Biosimilar market, revenue ($M), Indonesia, 2012–21

Figure 18: OTC market revenue ($B), Indonesia, 2013–21

Figure 19: OTC medicines market ($M), major distribution channels, Indonesia, 2021

Figure 20: OTC medicines market ($M), major categories, Indonesia, 2021

Figure 21: COVID-19 cases, Indonesia, 2020–22

Figure 22: COVID-19 deaths, Indonesia, 2020–22

Figure 23: COVID-19 stringency index (based on the share of people who are non vaccinated), Indonesia, 2020–22

Figure 24: COVID-19 containment and health index, Indonesia, 2020–22

Figure 25: COVID-19 fiscal stimulus timeline, Indonesia, 2020

Figure 26: COVID-19 approved vaccines, Indonesia, 2022

Figure 27: COVID-19 vaccination plan, Indonesia, 2022

Figure 28: COVID-19 vaccine distribution, Indonesia, 2022

Figure 29: COVID-19 clinical trials count by trial status, Indonesia, 2021–22

Figure 30: COVID-19 clinical trials count by trial phase, Indonesia, 2021–22

Figure 31: Top COVID-19 clinical trials sponsors by trial count, Indonesia, 2021–22

Figure 32: Medical devices market, revenue ($B), Indonesia, 2019–26

Figure 33: Medical devices market, revenue ($B) of major companies, Indonesia, 2020

Figure 34: Deal value and deal count, pharmaceutical market, Indonesia, 2020–22

Figure 35: Top therapy areas by deal count, pharmaceutical market, Indonesia, 2020–22

Figure 36: Deal value and deal count subtypes, pharmaceutical market, Indonesia, 2020–22

Figure 37: Deal value and deal count, medical devices market, Indonesia, 2020–22

Figure 38: Deal value and deal count subtypes, medical devices market, Indonesia, 2020–22

Figure 39: Deal value and deal count, quarterly, medical devices market, Indonesia, 2020–22

Figure 40: Top equipment sectors by deal value ($M), medical devices market, Indonesia, 2020–22

Figure 41: Top equipment sectors by deal count, medical devices market, Indonesia, 2020–22

Figure 42: M&A deals by quarter, medical devices market, Indonesia, 2020–22 (by value and by number)

Figure 43: VC deals by quarter, medical devices market, Indonesia, 2020–22 (by value and by number)

Figure 44: Programs for development of healthtech ecosystem, Indonesia, 2022

Figure 45: Deal value ($B) and deal count, Healthtech, Indonesia, 2020–22

Figure 46: Deal values ($B) and deal count by sector, Healthtech, Indonesia, 2020–22

Figure 47: Missions of Digital Transformation Program, Healthtech, Indonesia, 2022

Figure 48: Priority activity of blueprint for digital health transformation, Healthtech, Indonesia, 2022

Figure 49: Roadmap of health technology transformation, Healthtech, Indonesia, 2022

Figure 50: Telemedicine service flow as per the blueprint for the digital transformation, Healthtech, Indonesia, 2022

Figure 51: Overview of healthcare system, Indonesia, 2022

Figure 52: Total insured population and insurance per 1,000 residents, Indonesia, 2014–18

Figure 53: Indonesian residents without any insurance coverage, 2019

Figure 54: OOP expenditure (% of total expenditure on health), Indonesia, 2013–22

Figure 55: Annual rate of change (%), health price index, Indonesia, 2012–19

Figure 56: Organization of BPOM, Indonesia, 2022

Figure 57: Drug registration process, Indonesia, 2022

Figure 58: Traditional drug registration process, Indonesia, 2022

Figure 59: Halal drug registration process, Indonesia, 2022

Figure 60: Medical device classification as per the risk for patients, Indonesia, 2022

Figure 61: In vitro medical device classification as per the risk for individual and community, Indonesia, 2022

Figure 62: Medical device registration process, Indonesia, 2022

Figure 63: Organizational structure of DGIP, Indonesia, 2022

Figure 64: Patent approval process, Indonesia, 2022

Figure 65: Trademark registration process, Indonesia, 2022

Figure 66: Pre-marketing clinical trial approval, Indonesia, 2022

Figure 67: Post-marketing clinical trial approval, Indonesia, 2022

Figure 68: Pharmaceutical clinical trials count by trial status, Indonesia, 2021–22

Figure 69: Top five pharmaceutical clinical trials count by indication, Indonesia, 2021–22

Figure 70: Pharmaceutical clinical trials count by phase, Indonesia, 2021–22

Figure 71: Top four pharmaceutical clinical trials sponsors by count, Indonesia, 2021–22

Figure 72: Essential labeling requirements of medical devices, Indonesia, 2022

Figure 73: Missions of RPJMN, Indonesia, 2022

Figure 74: Indonesia Vision 2045

Figure 75: Strategies of eradicating caries, Indonesia, 2022

Figure 76: Number of hospitals, Indonesia, 2016–22

Figure 77: Number of hospitals by class, Indonesia, 2020

Figure 78: Hospital beds (per 1,000 population), Indonesia, 2015–22

Figure 79: Life expectancy at birth (years), Indonesia, 2013–22

Figure 80: Immunization rate (%), Indonesia, 2013–21

Figure 81: PM2.5 (µg per m3), Indonesia, 2013–22

Figure 82: CO2 emissions (metric tons per capita), Indonesia, 2013–22

Figure 83: Physicians (per 10,000 population), Indonesia, 2015–21

Figure 84: Pharmacists (per 10,000 population), Indonesia, 2015–21

Figure 85: Dentists (per 10,000 population), Indonesia, 2015–21

Figure 86: Nurses (per 10,000 population), Indonesia, 2015–21

Figure 87: Major causes of mortality (per 100,000 population), Indonesia, 2019

Figure 88: Major causes of male mortality (per 100,000 population), Indonesia, 2019

Figure 89: Major causes of female mortality (per 100,000 population), Indonesia, 2019

Figure 90: DALYs by major disease (per 100,000 population), Indonesia, 2019

Figure 91: Healthcare expenditure as a percentage of GDP (%), Indonesia, 2013–22

Figure 92: Health expenditure share (% of total health spending), Indonesia, 2013–22

Frequently asked questions

Indonesia Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape standard reports
Currency USD
$1,995

Can be used by individual purchaser only

Most Popular
$2,992

Can be shared by unlimited users within one corporate location e.g. a regional office

$3,990

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Indonesia Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Pharmaceuticals reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
$3,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Indonesia Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape in real time.

  • Access a live Indonesia Healthcare (Pharma and Medical Devices) Market Analysis, Regulatory, Reimbursement and Competitive Landscape dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more